Yedida Y Bogachkov PhD,  —

A woman carrying specific gene variants placing her at increased risk of developing atypical hemolytic uremic syndrome (aHUS) was diagnosed with the disease following COVID-19 vaccination, as described in a recent case report. “Given the short time lapse between vaccination … and the clinical manifestations, we believe that vaccine…

Soliris (eculizumab) prevented disease recurrence in a small group of patients with primary atypical hemolytic uremic syndrome (aHUS) after they underwent kidney transplantation, a recent study has found. The study, “Efficacy and Safety of Eculizumab in Kidney Transplant Patients With Primary Atypical Hemolytic-Uremic Syndrome,” was published in…

For this year’s Rare Disease Day on Feb. 28, the aHUS Alliance is asking patients and caregivers to join them in their project to showcase questions from those affected by atypical hemolytic uremic syndrome (aHUS). This project is aimed at raising awareness for those affected by aHUS.

Samsung Bioepis announced that its product SB12, a proposed biosimilar — a product that is highly similar, with no clinically meaningful differences, to an original patented product — to Soliris (eculizumab), showed equivalent properties with regards to the therapy’s safety, pharmacokinetics, and immune profile in a…